Checkpoint inhibitor-related immune-mediated encephalitis
From IDWiki
Background
- Causes include nivolumab/ipilimumab, pembrolizumab, atezolizumab, nivolumab/relatlimab
Clinical Manifestations
- Onset variable, days to weeks to months
- Symptoms are most frequently cognitive (confusion, agitation, altered mental status, memory impairment) and neuropsychiatric (behaviour changes, hallucinations, emotional lability)
- Can have headache, nausea/vomiting, fevers, confusion, gait impairment, dysautonomia, and seizures
- May be concurrent with other organ involvement, such as dermatitis, hepatitis, hypophysitis, and thyroiditis
Investigations
- MRI findings can include:
- Within normal limits
- Bilateral temporal or multiple T2/FLAIR lesions
- Leptomeningitial or dural enhancement, particularly in patients with CSF pleocytosis
- Can have an appearance typical for limbic encephalitis or autoimmune encephalitis
- CSF findings:
- Within normal limits about a quarter
- CSF pleocytosis is common, most commonly with lymphocyte predominance (occasionally neutrophilic)
- Elevated protein
- Negative flow cytometry and cytopathology
- May have one or more detectable autoantibodies, including anti-Hu, anti-Ma2, anti-GAD65, anti-GFAP, and anti-NMDAR
Management
- Discontinue the causative medication
- Methylprednisolone 500-1000 mg IV daily for 3 to 5 days followed by tapering corticosteroid
- Sometimes adjunctive IVIg is tried
- Recovery can take several weeks
Further Reading
- Immune-related encephalitis after immune checkpoint inhibitor therapy. Oncologist. 2025;30(1):oyae186. doi: 10.1093/oncolo/oyae186. PMID: 39066587; PMCID: PMC11783331.